This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MDT Stock Gains From FDA Approval for Its InPen App
by Zacks Equity Research
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
Here's Why Medtronic (MDT) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic Q2 Earnings and Revenues Top, Stock Down on Trimmed '25 View
by Zacks Equity Research
MDT delivers diversified growth across all its segments in the second quarter of fiscal 2025.
Compared to Estimates, Medtronic (MDT) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended October 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 1.61% and 1.75%, respectively, for the quarter ended October 2024. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 2% and 2.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Markets Wait for Last Significant Week of Q3 Earnings Season
by Zacks Equity Research
Markets Wait for Last Significant Week of Q3 Earnings Season.
Big Week for NVDA, Retail Earnings and Housing
by Mark Vickery
NVIDIA is the last of the Big Tech companies to report, joining Walmart (WMT), Target (TGT) and other retailers reporting this week.
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close.
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precigen (PGEN) delivered earnings and revenue surprises of -12.50% and 13.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Medtronic (MDT) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Medtronic (MDT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -11.76% and 43.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 310.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will ISRG Stock Continue Its Uptrend After Gaining 9.9% in a Month?
by Indrajit Bandyopadhyay
Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The stock also gained during the past month. Let's see if the trend might change.
The Zacks Analyst Blog Oracle, Micron Technology, Medtronic and The Cato
by Zacks Equity Research
Oracle, Micron Technology, Medtronic and The Cato are included in this Analyst Blog.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $87.72, representing a -0.45% change from its previous close.
Top Analyst Reports for Oracle, Micron Technology & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Micron Technology, Inc. (MU) and Medtronic plc (MDT), as well as a micro-cap stock The Cato Corporation (CATO).
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?
by Urmimala Biswas
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
National Vision (EYE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 140% and 0.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Medtronic (MDT) reachead $90.07 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
by Zacks Equity Research
Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Medtronic (MDT) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Medtronic (MDT) closed at $90.60, indicating a +0.01% shift from the previous trading day.
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $91.12, moving +0.1% from the previous trading session.
Bioventus Surges 73% in Three Months: Time to Buy the Stock?
by Sundeep Ganoria
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.